ARYLAMINE PROCESSES
    1.
    发明申请
    ARYLAMINE PROCESSES 审中-公开

    公开(公告)号:US20080076049A1

    公开(公告)日:2008-03-27

    申请号:US11535301

    申请日:2006-09-26

    CPC classification number: G03G5/0614 C07C227/16 C07C229/42

    Abstract: Continuous and batch processes for selectively hydrogenating double and/or triple bonds in organic molecules include providing at least one organic molecule containing a double and/or triple bond, providing at least one hydrogen donor molecule, and hydrogenating the double and/or triple bond in the presence of at least one catalyst. Continuous and batch processes for preparing arylamine molecules include selectively hydrogenating double bonds in arylamine compounds by providing at least one organic molecule containing a multiple bond, providing at least one hydrogen donor molecule, and hydrogenating the multiple bond in the presence of at least one catalyst. The continuous and batch processes provide efficient, cost-effective and safe methods for conducting selective hydrogenation reactions in the synthesis of organic molecules, such as charge-transport molecules.

    Abstract translation: 用于选择性氢化有机分子中的双键和/或三键的连续和间歇方法包括提供至少一种含有双键和/或三键的有机分子,提供至少一个氢供体分子,并将双键和/或三键氢化 存在至少一种催化剂。 用于制备芳基胺分子的连续和间歇方法包括通过提供至少一个含有多重键的有机分子选择性氢化芳基胺化合物中的双键,提供至少一个氢供体分子,并在至少一种催化剂存在下氢化多重键。 连续和间歇方法提供了在合成有机分子例如电荷传输分子中进行选择性氢化反应的有效,成本有效和安全的方法。

    Progesterone receptor transcript sequences
    3.
    发明申请
    Progesterone receptor transcript sequences 审中-公开
    孕激素受体转录本序列

    公开(公告)号:US20050255481A1

    公开(公告)日:2005-11-17

    申请号:US10843717

    申请日:2004-05-11

    CPC classification number: C12Q1/6886 C12Q2600/106 C12Q2600/112 C12Q2600/156

    Abstract: The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.

    Abstract translation: 本发明涉及鉴定和使用与乳腺癌相关的来自表达的孕酮受体转录物的序列。 特别地,本发明提供可用于鉴定对雌激素受体表达呈阳性的群体的多核苷酸序列的身份。 表达的多核苷酸序列可用于研究和/或诊断乳腺癌中的细胞和组织,以及用于研究和/或确定患者的预后。

    Solventless Reaction Process
    4.
    发明申请
    Solventless Reaction Process 审中-公开
    无溶剂反应过程

    公开(公告)号:US20120277462A1

    公开(公告)日:2012-11-01

    申请号:US13095015

    申请日:2011-04-27

    CPC classification number: C07C67/08 C07C2601/14 C07C69/704 C07C69/70

    Abstract: A process including reacting at least one organic acid with at least one compound of the formula R—OH, in the presence of an optional catalyst, in a reaction mixture wherein the reaction mixture is substantially free of solvent, to form a reaction product, wherein the reaction product is an ester of citric acid or an ester of tartaric acid; optionally, heating the reaction mixture; and optionally, isolating the reaction product.

    Abstract translation: 一种方法,包括使至少一种有机酸与至少一种式R-OH的化合物在任选的催化剂存在下在反应混合物中反应,其中反应混合物基本上不含溶剂,形成反应产物,其中 反应产物是柠檬酸或酒石酸酯的酯; 任选地,加热反应混合物; 并任选地分离反应产物。

    Diagnosis and treatment of breast cancer
    6.
    发明申请
    Diagnosis and treatment of breast cancer 审中-公开
    诊断和治疗乳腺癌

    公开(公告)号:US20060154267A1

    公开(公告)日:2006-07-13

    申请号:US11089097

    申请日:2005-03-24

    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.

    Abstract translation: 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志,其中签名与反应性或缺乏相关,与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本,并提供可靠的一组分子标准,用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物,用于通过使用多种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种抗雌激素剂对乳腺癌的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达,而另外两种生物标志物显示与他莫昔芬反应相关的降低的表达。

    Emulsion aggregation process for forming polyester toners
    7.
    发明授权
    Emulsion aggregation process for forming polyester toners 有权
    用于成型聚酯调色剂的乳液聚集方法

    公开(公告)号:US06395445B1

    公开(公告)日:2002-05-28

    申请号:US09817192

    申请日:2001-03-27

    CPC classification number: G03G9/0804

    Abstract: A process for forming toner particles includes aggregating the toner particles by adding an aggregating agent to a latex emulsion of resin having a colorant mixed therein, the adding being done under adding conditions of agitation and a temperature above a glass transition temperature of the resin, wherein the adding of the aggregating agent comprises first introducing at least about 40% by weight of a total amount of aggregating agent to be added at a rapid introduction rate and subsequently adding a remaining portion of the aggregating agent at a continuous addition rate slower than the rapid introduction rate. The particles are subsequently cooled to a temperature below the glass transition temperature of the resin when particles have been grown to the desired size.

    Abstract translation: 用于形成调色剂颗粒的方法包括通过向其中混合有着色剂的树脂的胶乳乳液中加入聚集剂来聚集调色剂颗粒,在搅拌条件和高于树脂的玻璃化转变温度的温度下进行添加,其中 聚集剂的添加包括首先引入至少约40重量%的以快速引入速率加入的总量的总量,然后以比快速的连续添加速率连续添加聚集剂的剩余部分 介绍率。 随后,当颗粒生长至所需尺寸时,随后将颗粒冷却至低于树脂玻璃化转变温度的温度。

Patent Agency Ranking